Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) launched a real-world, Phase 4 study to evaluate the long-term effects of the Aduhelm (aducanumab-avwa) 100 mg/mL solution...
ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practiceICARE AD-US is one of three programs to...
Biogen (BIIB) has been in the headlines after FDA approved the company’s Alzheimer's disease drug Aduhelm (aducanumab), in a controversial decision that went against the advisory...
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 576.00 | 580.80 | 567.00 | +3.20 | +0.56% | 9.23M | London | |||
| 387.30 | 392.50 | 387.30 | -5.80 | -1.48% | 6.73M | London | |||
| 159.20 | 165.40 | 154.00 | +0.60 | +0.38% | 271.15K | London | |||
| 164.60 | 166.15 | 164.00 | -1.45 | -0.87% | 6.02M | London | |||
| 6.45 | 6.45 | 6.45 | +0.15 | +2.38% | 7.07M | London | |||
| 1,444.80 | 1,481.20 | 1,439.80 | -66.8 | -4.42% | 880.71K | London | |||
| 703.60 | 709.40 | 695.40 | -7.20 | -1.01% | 1.25M | London | |||
| 1,521.00 | 1,541.00 | 1,495.00 | -32.50 | -2.09% | 2.81M | London | |||
| 1,192.50 | 1,212.00 | 1,185.00 | -12.00 | -1.00% | 194.07K | London | |||
| 2,755.00 | 2,812.00 | 2,731.00 | -37.0 | -1.32% | 169.12K | London | |||
| 1,135.00 | 1,165.00 | 1,116.00 | -30.00 | -2.58% | 87.79K | London | |||
| 7,490.00 | 7,492.00 | 7,238.00 | +172.0 | +2.35% | 641.73K | London | |||
| 644.00 | 648.20 | 637.60 | -4.60 | -0.71% | 460.12K | London | |||
| 63.56 | 68.54 | 63.26 | -3.28 | -4.91% | 5.78M | London | |||
| 1,417.80 | 1,421.00 | 1,398.40 | +11.40 | +0.81% | 7.22M | London |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
